Introduction
Intellectual Property Rights (IPRs) are legal rights that recognise creations of the mind. Among these, patents are a crucial form of protection, granting an inventor the exclusive right to their invention for a limited period. In India, the patent regime is primarily governed by the Patents Act, 1970. This statutory framework provides a detailed mechanism for the registration and protection of patents, which in turn secures the rights of the patentee. These rights, however, do not exist in a vacuum. They operate within the broader constitutional landscape of India, which seeks to balance private rights with public interest. This essay will explain how patent registration protects the rights of the patentee in India by examining the provisions of the Patents Act, 1970. It will then analyse this protection with reference to the Constitution of India, showing how a patent is treated as a form of property and how the exercise of patent rights is balanced against fundamental constitutional principles, particularly the right to health.
Statutory Protection for the Patentee
The primary instrument for the protection of a patentee’s rights in India is the Patents Act, 1970 (the Act). The Act establishes a comprehensive system through which an inventor can secure a legal monopoly over their invention. Upon meeting the statutory requirements of novelty, inventive step, and industrial applicability (Patents Act, 1970, s. 2(1)(j)), an inventor is granted a patent. This grant confers a set of powerful exclusive rights upon the patentee.
Section 48 of the Act is the cornerstone of a patentee’s protection. It explicitly grants the patentee the exclusive right "to prevent third parties, who do not have his consent, from the act of making, using, offering for sale, selling or importing for those purposes" the patented product or process in India (Patents Act, 1970, s. 48). This provision effectively creates a legal shield around the invention, allowing the patentee to control its commercial exploitation. This exclusivity is the primary reward for the inventor's investment of time, intellect, and resources, creating a strong incentive for innovation and technological advancement (Bently et al., 2022). The protection is not indefinite; Section 53 of the Act specifies that the term of a patent is twenty years from the date of filing the patent application, providing a substantial but limited period for the patentee to benefit from the monopoly.
To give these rights practical effect, the Act provides for civil remedies against infringement. When a third party violates the exclusive rights granted under Section 48, the patentee can initiate infringement proceedings. The remedies available, as outlined in Section 108, include injunctions to stop the infringing activity and an order for either damages or an account of profits. An injunction is a powerful tool as it can prevent further commercial damage to the patentee, while the option of damages or an account of profits ensures that the patentee is compensated for the economic harm suffered due to the infringement. Together, these provisions form a robust mechanism that protects the patentee's commercial and proprietary interests in their invention.
The Constitutional Status of a Patent as Property
The rights granted under the Patents Act are not merely statutory benefits; they are also recognised and protected within the constitutional framework of India. While the Constitution of India does not explicitly mention intellectual property, a patent is widely regarded as a form of intangible property (Saha, 2011). This classification is significant because it brings patent rights under the purview of Article 300A of the Constitution.
Article 300A states: "No person shall be deprived of his property save by authority of law." Originally a fundamental right, the right to property was repositioned as a constitutional right by the 44th Amendment in 1978. Nevertheless, it remains a vital safeguard against arbitrary state action. By classifying a patent as 'property', Article 300A ensures that the state cannot extinguish or acquire a patentee's rights without a clear legal mandate and procedure (Basu, 2020).
The "authority of law" in this context is the Patents Act itself. The Act lays down the precise circumstances under which a patent can be granted, refused, or revoked. For example, Sections 64 and 66 of the Act list the grounds on which a patent may be revoked, such as the invention not being new, lack of an inventive step, or the patent being obtained on a false suggestion. This means that while a patentee's property right is not absolute and can be taken away, its deprivation must follow the due process established by law, preventing arbitrary executive action. Therefore, the Constitution provides a foundational layer of protection for the patentee, guaranteeing that their legally-granted rights cannot be nullified without just and legal cause.
Constitutional Balancing: Patent Rights and Public Interest
Despite the strong statutory and constitutional protection afforded to patentees, these rights are not absolute. The Indian Constitution is a social document that aims to promote the welfare of its people. As such, private rights are often balanced against the larger public interest. This is particularly evident in the field of patent law, where the monopoly granted to a patentee can conflict with other fundamental rights, most notably the Right to Health, which the Supreme Court of India has read into the Right to Life under Article 21 (Constitution of India, 1950).
The tension is most pronounced in the pharmaceutical sector, where a patent on an essential medicine can lead to high prices, making it inaccessible to large sections of the population. This directly challenges the State's duty to ensure the health and well-being of its citizens. The Indian legal system addresses this conflict not by denying patent protection outright, but by building safeguards into the Patents Act that reflect these constitutional considerations. These safeguards act as a check on the patentee's monopoly.
One of the most significant balancing mechanisms is the provision for compulsory licensing under Sections 84-92 of the Act. Section 84 allows for a compulsory licence to be granted if, after three years from the grant of a patent, the reasonable requirements of the public have not been satisfied, the patented invention is not available to the public at a reasonably affordable price, or the patented invention is not worked in the territory of India. This was famously invoked in the case of Bayer Corporation v. Union of India (2014), where India's first compulsory licence was granted to Natco Pharma for the cancer drug Sorafenib Tosylate, on the grounds that Bayer was not making the drug available at a reasonably affordable price. This provision ensures that a patentee cannot abuse their monopoly at the expense of public health.
Furthermore, Section 3(d) of the Act is a unique provision designed to prevent the "evergreening" of patents, where pharmaceutical companies make minor changes to existing drugs to extend their patent monopoly. The section clarifies that a new form of a known substance is not considered an invention unless it "results in the enhancement of the known efficacy of that substance". The Supreme Court upheld the constitutionality and interpretation of this provision in the landmark case of Novartis AG v. Union of India (2013), where it denied a patent for the cancer drug Glivec. The Court emphasised that the Indian patent regime is designed to balance the need for innovation with the public's interest in accessing medicines. These provisions demonstrate that while the system protects the patentee, this protection is qualified to serve the broader constitutional mandate of public welfare.
Conclusion
In conclusion, the system of patent registration in India offers significant and structured protection for the rights of a patentee. The principal source of this protection is the Patents Act, 1970, which grants exclusive rights to make, use, sell, and import the invention, supported by robust remedies for infringement. This statutory right is elevated to a constitutional level, as a patent is treated as a form of property protected under Article 300A of the Constitution, safeguarding it from arbitrary deprivation by the state. However, this protection is not absolute. The Indian framework performs a delicate balancing act, weighing the patentee's private rights against the overarching constitutional imperatives of public health and welfare, particularly those derived from Article 21. Mechanisms within the Patents Act, such as compulsory licensing and the strict patentability criteria under Section 3(d), serve as important checks on patent monopolies. Therefore, the Indian approach protects the patentee to incentivise innovation, but does so within a constitutional framework that ensures these rights do not unduly compromise the public interest.
References
Basu, D.D. (2020) Introduction to the Constitution of India. 24th edn. LexisNexis.
Bently, L., Sherman, B., Gangjee, D. and Johnson, P. (2022) Intellectual Property Law. 6th edn. Oxford University Press.
Bayer Corporation v Union of India & Ors [2014] W.P.(C) 1379/2013 (High Court of Delhi).
Constitution of India, 1950.
Novartis AG v Union of India & Ors [2013] 6 SCC 1.
The Patents Act, 1970 (Act 39 of 1970) (India).
Saha, T. K. (2011) Law of Intellectual Property Rights. 1st edn. Universal Law Publishing.
